Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Blood Culture Use in Medical and Surgical Intensive Care Units and Wards.
JAMA Netw Open
January 2025
Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Importance: Blood culture (BC) use benchmarks in US hospitals have not been defined.
Objective: To characterize BC use in adult intensive care units (ICUs) and wards in US hospitals.
Design, Setting, And Participants: A retrospective cross-sectional study of BC use in adult medical ICUs, medical-surgical ICUs, medical wards, and medical-surgical wards from acute care hospitals from the 4 US geographic regions was conducted.
Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events.
Pharmacoepidemiol Drug Saf
January 2025
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Introduction: Masking is a reporting bias where drug safety signals are muffled by elevated reporting of other medications in spontaneous reporting databases. While the impact of masking is often limited, its effect when using restricted designs, such as active comparators, can be consequential.
Methods: We used data from the US Food and Drugs Administration Adverse Event Reporting System (1999Q3-2013Q3) to study masking in a real-world example.
Article Synopsis
- The text discusses the importance of forecasting future health issues in the USA for effective planning and public awareness regarding disease and injury burdens.
- It describes the methodology for predicting life expectancy, cause-specific mortality, and disability-adjusted life-years (DALYs) from 2022 to 2050 using the Global Burden of Diseases framework.
- The forecasting includes various scenarios to assess the potential impacts of health risks and improvements across the country, focusing on demographic trends and health-related risk factors.
Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database.
Ther Innov Regul Sci
January 2025
Guangdong Province Hospital for Occupational Disease Prevention and Treatment, Guangzhou, China.
Background And Objective: Denosumab is widely used for osteoporosis and cancer treatment. However, hypocalcemia induced by denosumab is a frequent adverse event. The objective of this study is to comprehensively investigate the safety signals and the occurrence of hypocalcemia in real-world patient cases reported through the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
View Article and Find Full Text PDFSafety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.
Lancet Microbe
November 2024
Division of Biostatistics, University of Minnesota, Minneapolis, MN, USA.
Article Synopsis
- rVSVΔG-ZEBOV-GP is a vaccine that helps protect people from the Ebola virus and is the first one to be officially approved for this purpose.
- This study wanted to see how well a booster shot given 18 months after the first vaccine dose helped keep the immune response strong for a longer time.
- Healthy adults who might be at risk of exposure to Ebola participated in the trial, and the results measured their antibody levels 36 months after the first vaccination to compare those who got the booster with those who did not.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!